Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a second-generation antihistamine drug without sedative or antimuscarinic effects (AEMPS 2016, Wolthers 2013, Scaglione 2012, Conen 2011, Church 2011).
At latest update, relevant data on its excretion into breast milk were not found.
Due to a lack of sedative effect since it does not break through the blood-brain barrier (Scaglione 2012, Church 2011), and, a favorable pharmacokinetic profile (Togawa 2016, AEMPS 2016, Sádaba 2013), -high protein-binding capacity, and a medium oral bioavailability-, the risk for problems in the nursing infant is very low. However, until more and reliable data on this drug concerning breastfeeding is available, known safer options should be preferred, especially for breastfeeding mothers in the first month after birth or in case of prematurity.